SVIL通过TGF-β/Smad通路在缺氧条件下促进卵巢癌进展和上皮-间质转化
该研究筛选出缺氧相关靶点SVIL,在临床样本和细胞缺氧模型中评估其对卵巢癌进展和转移的影响,并用裸鼠原位瘤模型验证。结果显示SVIL在卵巢癌缺氧环境中高表达且与患者预后相关,敲低SVIL可抑制TGFβ1/smad2/3通路激活,减弱进展和上皮-间质转化,并通过增加顺铂诱导的凋亡缓解顺铂耐药;裸鼠模型中敲低SVIL显著抑制肿瘤生长和转移。作者认为SVIL可能是卵巢癌治疗的新靶点。
要点
- SVIL在卵巢癌缺氧环境中显著高表达,且其表达与患者预后相关。
- 敲低SVIL抑制TGFβ1/smad2/3通路激活,减弱卵巢癌进展和上皮-间质转化。
- 敲低SVIL通过增加顺铂诱导的凋亡缓解顺铂耐药,并在裸鼠原位模型中抑制肿瘤生长和转移。
核心结论
- SVIL在缺氧微环境中高表达,可通过激活TGFβ1/smad2/3通路增加卵巢癌进展和顺铂耐药。
- 作者认为SVIL可能是卵巢癌治疗的新靶点。
研究设计与样本
- 研究筛选SVIL为卵巢癌缺氧相关靶点,并在临床样本和细胞缺氧模型中评估SVIL对卵巢癌进展和转移的影响。
- 研究使用裸鼠原位肿瘤模型确认SVIL对卵巢癌进展的影响。
主要发现
- SVIL在卵巢癌缺氧环境中显著高表达,SVIL表达与患者预后相关。
- CCK8、划痕实验、Transwell实验、Western Blot和凋亡实验显示,敲低SVIL抑制TGFβ1/smad2/3通路激活,减弱卵巢癌进展和上皮-间质转化,并通过增加顺铂诱导的凋亡缓解顺铂耐药。
- 裸鼠卵巢癌原位模型中,敲低SVIL显著抑制肿瘤生长和转移。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ovarian cancer is the malignant tumor with the highest mortality rate in gynecology. We aimed to identify novel genes that promote ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions. METHODS: We screened SVIL as a hypoxia-associated target in ovarian cancer and explored the related molecular mechanisms. We assessed the effects of SVIL on ovarian cancer progression and metastasis in clinical samples and cellular hypoxia models. Further, we investigated the relevant pathways of SVIL and confirmed the effects of SVIL on ovarian cancer progression by using nude mouse in situ tumor models. RESULTS: We found that SVIL was significantly highly expressed in the hypoxic environment of ovarian cancer, and SVIL expression correlated with patient prognosis.CCK8, Wound-healing assay, Transwell assay, Western Blot, and apoptosis assays revealed that knockdown of SVIL inhibited the activation of the TGFβ1/smad2/3 pathway, which attenuated the progression and epithelial-mesenchymal transition(EMT) of ovarian cancer and alleviated cisplatin resistance by increasing cisplatin-induced apoptosis. Furthermore, in a nude mouse ovarian cancer in situ model, we found that the knockdown of SVIL significantly inhibited tumor growth and metastasis. CONCLUSION: SVIL highly expressed in the hypoxic microenvironment can increase ovarian cancer progression and cisplatin resistance by activating TGFβ1/smad2/3 pathway. Our study demonstrated that SVIL may be a novel target for the treatment of ovarian cancer.
引用
- Dai D, Li C, Xia H, et al. SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-β/Smad pathway. Gynecol Oncol. 2024. PMID: 39197416. doi:10.1016/j.ygyno.2024.07.688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。